Supplementary material to article by C. Dannepond et al. "Serum Infliximab Concentrations in Psoriatic Patients Treated with Infliximab: A Systematic Review"

	Infliximab regimen			Measurement of serum infliximab concentration	
Author, year	Dose (mg/kg)	Time of infusions, week (W)	Dosage adjustment ^b	Technique of measurement	Time of measurement
Gottlieb, et al., 2003 (26)	2 groups: 5.0 and 10.0	W0, W2, W6	No	ELISA	Before and 1 h after infusion W0, W2, W6, W10, W14
Reich, et al., 2005 (3)	5.0	W0, W2, W6 and every 8 weeks (W0 to W46)	No	Not available	Before and after infusion W0, W2, W6, W10, W14, W22, W30, W38, W46, W50
Menter, et al., 2007 (27)	2 groups: 3.0 and 5.0	W0, W2, W6 and every 8 weeks (W0 to W46) or intermittent	No	ELISA	Before infusion W0, W10, W14, W18, W22, W26, W30, W34, W38, W42, W46, W50
Zhu, et al., 2006 (33)	2 groups: 3.0 and 5.0	W0, W2, W6 and every 8 weeks (W0 to W46) or intermittent	No	ELISA	Before infusion W0, W10, W14, W18, W22, W26, W30, W34, W38, W42, W46, W50
Torii & Nakagawa 2010 (28)	1 5.0	W0, W2, W6 and every 8 weeks (W0 to W62)	No	ELISA (Biotech Janssen antibodies)	Before and 1 h after infusion: W0, W2, W6 Before infusion: W10, W14, W22, W30, W38, W46, W54, W62, W70, W78
Torii & Nakagawa 2011 (29)	1 5.0	W0, W2, W6 and every 8 weeks (W0 to W46)	No	ELISA (Biotech Janssen antibodies)	Before and 1 h after infusion: W0, W2, W6 Before infusion: W10, W14, W22, W30, W38, W46, W50
Torii, et al., 2012 (34)	5.0	W0, W2, W6 and every 8 weeks (W0 to W46 or W62)	No	ELISA (Biotech Janssen antibodies)	Before infusion W0, W2 and every 4 weeks to W50 or W70
Takahashi, et al., 2012 (30)	Mean=4.6 Ranges=4.1-5.2	W0, W2, W6 and every 8 weeks (W0 to W48)	No	ELISA (kit Matriks Biotech Laboratories, Ankara, Turkey)	Before infusion: W48
Gottlieb, et al., 2012 (31)	5.0	W0, W2, W6 and every 8 weeks (W0 to W22)	no	Not available	Before infusion W0, W2, W6, W14, W22, W26
Meyer, et al., 2012 (32)	2 Median=5.1 Ranges=4.6–6.5	Median=8 weeks Ranges=6–8	Yes ^b	RadioImmunoAssay	Before infusion Measurement between 18 and 120 months after the initiation of treatment (median 58 months)

Table SI. Characteristics of infliximab treatment and methods of measurement of serum infliximab concentration
--

^aDosage adjustment defined by modification of infliximab dosage and/or intervals between 2 infusions. ^bIncreasing dosage and decreasing interval. ELISA: Enzyme-linked immunosorbent assay.